Boston Scientific Corporation
Rank #220HypergrowthBSX · NYSE · Healthcare
Boston Scientific Corporation (BSX) — Rank #220 by gross profitability (GP/assets 0.31) · ROE 11.6% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0000885725 · all metrics point-in-time as of the filing date.
About
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Show moreShow less
The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer.
The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- bostonscientific.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowstable
- Gross marginstable
- Gross profitabilitydeteriorating
- Net cashimproving
- Operating marginimproving
- Return on equityimproving
- Share count (dilution)deteriorating
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2020-12-31filed 2021-02-23 | 2019-12-31filed 2020-02-25 | 2018-12-31filed 2019-02-19 | 2017-12-31filed 2019-02-19 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 9,913.0 | 10,735.0 | 9,823.0 | 9,048.0 |
| Revenue growth (YoY) | 22.9% | 33.1% | 21.8% | 21.8% |
| Gross profit | 6,448.0 | 7,620.0 | 7,011.0 | 7,011.0 |
| Gross margin | 65.0% | 71.0% | 71.4% | 71.4% |
| Net income | (115.0) | 4,700.0 | 1,671.0 | 104.0 |
| Net margin | -1.2% | 43.8% | 17.0% | 17.0% |
| EPS (diluted) | -$0.08 | $3.33 | $1.19 | $0.08 |
| EPS growth (YoY) | -102.4% | 179.8% | 1387.5% | — |
| Cash flow | ||||
| Operating cash flow | 1,508.0 | 1,836.0 | 310.0 | 1,426.0 |
| Capital expenditures | 376.0 | 461.0 | 316.0 | — |
| Free cash flow | 1,132.0 | 1,375.0 | (6.0) | (6.0) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?